 SAN DIEGO--BUSINESS WIRE--Odonate Therapeutics, Inc. NASDAQ: ODT, a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and nine months ended September 30, 2020. As of September 30, 2020, Odonate had 188.3 million in cash, compared to 180.5 million as of December 31, 2019. This increase in cash resulted primarily from the receipt of 87.4 million of net 